Abstract
Adding rivaroxaban to standard therapy in patients with heart failure and no atrial fibrillation did not show any beneficial effect on death risk.
MeSH terms
-
Atrial Fibrillation*
-
Factor Xa Inhibitors
-
Heart Failure*
-
Humans
-
Rivaroxaban
-
Stroke*
Substances
-
Factor Xa Inhibitors
-
Rivaroxaban